Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625737 | 0.85 | HDAC6 (0.40) | KDM4EALDH1A1POLB | |
| SCHEMBL9105728 | 0.78 | NPC1 (0.53) | CYP11B1CYP11B2TSHRPTPN1POLB | |
| SCHEMBL3567444 | 0.76 | PTGS2 (0.38) | KDM4EALDH1A1EGFRPOLB | |
| SCHEMBL3568292 | 0.75 | MEN1 (0.34) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL30819807 | 0.70 | CYP1A2 (0.47) | KDM4ECYP1A2CYP2C19PTPN1MTNR1A | |
| SCHEMBL31681025 | 0.70 | CYP1A2 (0.47) | KDM4ECYP1A2CYP2C19PTPN1MTNR1A | |
| SCHEMBL8017451 | 0.68 | MTNR1A (0.48) | CYP11B1CYP11B2KDM4EALDH1A1MTNR1A | |
| SCHEMBL689437 | 0.68 | MCL1 (0.56) | KDM4EALDH1A1CYP1A2TSHRPOLB | |
| SCHEMBL689438 | 0.68 | HPGD (0.35) | KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3565037 | 0.68 | KDM4E (0.45) | KDM4ECYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| CN-101128424-A | Indole compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | CYP11B1 441/4885CYP11B2 445/4885KDM4E 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.